Category: Research
... of PPP2R2A are highly sensitive to two specific classes of anticancer drugs: PARP inhibitors, and PP2A activating drugs. This project will test whether tumours with PPP2R2A loss will respond to ...
Category: News & Articles
... cancer researchers in the development of new anti-cancer drugs, ensuring the best outcomes for patients.
The Ramaciotti ... cancer researchers in the development of new anti-cancer drugs, ensuring the best outcomes for patients.
The Ramaciotti Foundations ...
Category: News & Articles
... PP2A in AML, the team are able to target this protein using drugs to restore PP2A activity, killing the tumour cells. Importantly it was ...
Category: News & Articles
...
“There’s still a lot of unmet need. KEYTRUDA drugs currently have response rates in the order of 30 to 50 per cent and ...
Category: Research
Fluoropyrimidines (5-FU and capecitabine) are anticancer drugs commonly used in a range of cancers including oesophageal, gastric and ...
Category: Research
... 2014, researchers reported a new combination of anti-cancer drugs and radiation which was successful in treating men with newly-diagnosed ...
Category: Researcher Profiles
... over time. Ultimately, my goal is to design more effective drugs that prevent cancer or prevent it coming back in patients after treatment ... patients, in order to better understand the actions of these drugs and to identify markers that predict treatment response. This will lead ...
Category: News & Articles
... hold true at the 10-year patient follow-up in 2017. As all drugs used in the trials are already in widespread use, these treatments could ...
Category: News & Articles
... Professor Hondermarck adds. “In the future, anti-cancer drugs could potentially block the stimulatory impact of nerves.”
There is ...
